quinoxalines has been researched along with adenosine diphosphate in 10 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (20.00) | 18.7374 |
1990's | 3 (30.00) | 18.2507 |
2000's | 5 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Paris, H; Remaury, A | 1 |
Flavahan, NA; Shimokawa, H; Vanhoutte, PM | 1 |
Hollier, LH; Miller, VM; Reigel, MM; Vanhoutte, PM | 1 |
Cambria, RA; Gloviczki, P; Lowell, RC; Miller, VM | 1 |
Flavahan, NA | 1 |
Magid, KS; Megson, IL; Shaw, CA; Sogo, N; Webb, DJ | 1 |
Duszyk, M; Jurasz, P; Mayers, I; Miranda, C; Radomski, MW; Sawicka, J; Sawicki, G | 1 |
Anfossi, G; Cavalot, F; Massucco, P; Mattiello, L; Russo, I; Trovati, M | 1 |
Homer, KL; Wanstall, JC | 1 |
Badimon, L; Salas, E; Segalés, E; Vilahur, G | 1 |
10 other study(ies) available for quinoxalines and adenosine diphosphate
Article | Year |
---|---|
The insulin-secreting cell line, RINm5F, expresses an alpha-2D adrenoceptor and nonadrenergic idazoxan-binding sites.
Topics: Adenosine Diphosphate; Adrenergic alpha-Antagonists; Animals; Binding Sites; Brimonidine Tartrate; Cell Line; Cyclic AMP; Dioxanes; GTP-Binding Proteins; Idazoxan; Immunoblotting; Insulin; Insulin Secretion; Kinetics; Membranes; Pertussis Toxin; Quinoxalines; Rats; Receptors, Adrenergic, alpha; Tritium; Virulence Factors, Bordetella; Yohimbine | 1992 |
Natural course of the impairment of endothelium-dependent relaxations after balloon endothelium removal in porcine coronary arteries. Possible dysfunction of a pertussis toxin-sensitive G protein.
Topics: Adenosine Diphosphate; Animals; Antihypertensive Agents; Blood Platelets; Bradykinin; Brimonidine Tartrate; Calcimycin; Coronary Vessels; Dinoprost; Endothelium, Vascular; In Vitro Techniques; Muscle Relaxation; Muscle, Smooth, Vascular; Nitric Oxide; Nitroprusside; Pertussis Toxin; Potassium Chloride; Quinoxalines; Serotonin; Swine; Thrombin; Virulence Factors, Bordetella | 1989 |
Endothelium-dependent responses in autogenous femoral veins grafted into the arterial circulation of the dog.
Topics: Acetylcholine; Adenosine Diphosphate; Adrenergic alpha-Agonists; Animals; Arachidonic Acid; Arachidonic Acids; Arteries; Brimonidine Tartrate; Calcimycin; Dogs; Endothelium; Femoral Vein; Indomethacin; Male; Muscle Relaxation; Muscle, Smooth, Vascular; Quinoxalines; Thrombin | 1987 |
Chronic changes in blood flow alter endothelium-dependent responses in autogenous vein grafts in dogs.
Topics: Acetylcholine; Adenosine Diphosphate; Adrenergic alpha-Agonists; Animals; Arginine; Arteriovenous Shunt, Surgical; Blood Flow Velocity; Brimonidine Tartrate; Calcimycin; Constriction; Dinoprost; Dogs; Endothelins; Endothelium, Vascular; Femoral Artery; Femoral Vein; Hyperplasia; Male; Models, Biological; Neovascularization, Pathologic; Nitric Oxide; omega-N-Methylarginine; Quinoxalines; Thrombin; Tunica Intima; Vascular Patency | 1994 |
Lysophosphatidylcholine modifies G protein-dependent signaling in porcine endothelial cells.
Topics: Adenosine Diphosphate; Animals; Bradykinin; Brimonidine Tartrate; Coronary Vessels; Dinoprost; Endothelium, Vascular; Female; Fluorides; GTP-Binding Proteins; Lysophosphatidylcholines; Male; Muscle Contraction; Pertussis Toxin; Quinoxalines; Serotonin; Signal Transduction; Swine; Virulence Factors, Bordetella | 1993 |
Inhibition of human platelet aggregation by nitric oxide donor drugs: relative contribution of cGMP-independent mechanisms.
Topics: Adenosine Diphosphate; Adult; Blood Platelets; Collagen; Cyclic GMP; Enzyme Inhibitors; Glucosamine; Glutathione; Humans; In Vitro Techniques; Kinetics; Models, Biological; Nitric Oxide Donors; Nitroglycerin; Nitroprusside; Nitroso Compounds; Oxadiazoles; Penicillamine; Platelet Aggregation; Platelet Aggregation Inhibitors; Quaternary Ammonium Compounds; Quinoxalines; S-Nitrosoglutathione | 2000 |
Matrix metalloproteinase 2 in tumor cell-induced platelet aggregation: regulation by nitric oxide.
Topics: Adenosine Diphosphate; Blood Platelets; Cell Communication; Enzyme Inhibitors; Epoprostenol; Fibrosarcoma; Gelatinases; Glutathione; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Neoplasms, Experimental; Nitric Oxide; Nitric Oxide Donors; Nitroso Compounds; Oxadiazoles; Penicillamine; Peptides, Cyclic; Platelet Aggregation; Platelet Aggregation Inhibitors; Quinoxalines; S-Nitroso-N-Acetylpenicillamine; S-Nitrosoglutathione; Thromboxane A2; Tumor Cells, Cultured | 2001 |
N-acetyl-L-cysteine exerts direct anti-aggregating effect on human platelets.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Acetylcysteine; Adenosine Diphosphate; Adult; Calcimycin; Cell Membrane Permeability; Collagen; Cyclic GMP; Dose-Response Relationship, Drug; Enzyme Inhibitors; Guanylate Cyclase; Humans; Ionomycin; Male; omega-N-Methylarginine; Oxadiazoles; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinones; Quinoxalines | 2001 |
Inhibition of rat platelet aggregation by the diazeniumdiolate nitric oxide donor MAHMA NONOate.
Topics: Adenosine Diphosphate; Animals; Catalase; Collagen; Cyclic GMP; Dose-Response Relationship, Drug; Enzyme Activators; Enzyme Inhibitors; Guanylate Cyclase; Hydrazines; In Vitro Techniques; Indazoles; Male; Nitric Oxide Donors; Oxadiazoles; Platelet Aggregation; Platelet Aggregation Inhibitors; Pulmonary Artery; Quinoxalines; Rats; Rats, Wistar; S-Nitrosoglutathione; Superoxide Dismutase; Thapsigargin; Thionucleotides; Vasoconstriction | 2002 |
Effects of a novel platelet nitric oxide donor (LA816), aspirin, clopidogrel, and combined therapy in inhibiting flow- and lesion-dependent thrombosis in the porcine ex vivo model.
Topics: Adenosine Diphosphate; Amino Acids; Animals; Aspirin; Benzoates; Blood Pressure; Clopidogrel; Collagen; Cyclooxygenase Inhibitors; Drug Evaluation; Drug Therapy, Combination; Fibrinolytic Agents; Free Radical Scavengers; Guanylate Cyclase; Heart Rate; Hemorheology; Imidazoles; Membrane Proteins; Nitric Oxide; Nitric Oxide Donors; Nitroso Compounds; Oxadiazoles; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Quinoxalines; Random Allocation; Receptors, Purinergic P2Y12; rhoA GTP-Binding Protein; Sus scrofa; Thrombosis; Ticlopidine | 2004 |